Figure 3C (Supplementary Fig. 2C) shows that cancer cells treated with combination of methyl gallate and low dose oxaliplatin (i.e. 10 μM) displayed an overall significant induction of CD112, CD155, ULBP-1, ULBP-2, ULBP-3, DR4, and DR5 (p < 0.05, p < 0.01). Here, TNFRSF10B is linked to cancer.